

Information Provided Under the Authority of ANSM

November 2019

Finasteride 1 mg (PROPECIA and its generics) Information sheet for patients

Editor's note: This English translation from the French text was done by a third party. The original ANSM letter can be accessed at [MSD France](#).

Dear Madam, Dear Sir, Dear Colleagues (letter intended for dermatologists, general practitioners and pharmacists):

You will find attached an information sheet for patients being treated with finasteride 1 mg or for whom finasteride 1 mg treatment is being considered. You should hand this document to them when prescribing or dispensing this medication.

The purpose of this information sheet is to inform patients about the potential risks associated with taking finasteride 1 mg when prescribed to treat slightly advanced androgenetic alopecia. As announced in a February 2019 Information Point¹ distributed by the National Agency for the Safety of Medicines and Health Products (ANSM), this document was prepared after consultation with healthcare professionals and patient associations. It supplements information in the current product insert.

If you wish to obtain additional copies, you can request them from the manufacturers via the links below.

This Patient Info sheet can also be downloaded from the ANSM website: <http://ansm.sante.fr>

Thank you for considering this information.

Manufacturer	Patient Info Card Order: Point of Contact
ARROW	infomed@laboratoire-arrow.com -Tél: 04 72 71 63 97
BAILLEUL	service-clients@bailleul.com
BIOGARAN	www.biogaran.fr -Tél: 0800 970109
CRISTERS	pharmacovigilance@cristers.com –Tél: 01 42 04 94 20
EG Labo	www.eqlabo.frou pharmacovigilance@eqlabo.com
MYLANSAS	www.mylan.fr (rubrique: Informations de sécurité)-Tél: 0 800 12 35 50
MSD France	www.msd-france.com www.msdconnect.fr
SANDOZ	www.sandoz.fr -Information médicale et Pharmacovigilance -Tél : 0800 455 799
TEVASANTE	www.teva-sante.fr -Tél : 0800 513411
ZYDUS	contact@zydusfrance.com -Tél : 01 41 19 18 50

Adverse reaction reporting

Immediately report any adverse reactions suspected to be due to a drug to your Regional Pharmacovigilance Center or on www.signalement-sante.gouv.fr. For more information on medicines, see ansm.sante.fr ou base-donnees-publique.medicaments.gouv.fr

¹ <https://www.ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Finasteride-rappel-sur-les-risques-de-troubles-psychiatriques-et-de-la-fonction-sexuelle-Point-d-Information>